Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: Subgroup analysis of a randomized phase 3 trial

  1. Zinzani, P.L.
  2. Khuageva, N.K.
  3. Wang, H.
  4. Garicochea, B.
  5. Walewski, J.
  6. Van Hoof, A.
  7. Soubeyran, P.
  8. Caballero, D.
  9. Buckstein, R.
  10. Esseltine, D.-L.
  11. Theocharous, P.
  12. Enny, C.
  13. Zhu, E.
  14. Elsayed, Y.A.
  15. Coiffier, B.
Revista:
Journal of Hematology and Oncology

ISSN: 1756-8722

Ano de publicación: 2012

Volume: 5

Tipo: Artigo

DOI: 10.1186/1756-8722-5-67 GOOGLE SCHOLAR lock_openAcceso aberto editor